AustralieFrV1, PubMed, Curation, bibRecord, 002184

Effects of Surface Composition on the Aerosolisation and Dissolution of Inhaled Antibiotic Combination Powders Consisting of Colistin and Rifampicin.

Identifieur interne : 002184 ( PubMed/Curation ); précédent : 002183; suivant : 002185

Effects of Surface Composition on the Aerosolisation and Dissolution of Inhaled Antibiotic Combination Powders Consisting of Colistin and Rifampicin.

Auteurs : Wenbo Wang [Danemark] ; Qi Tony Zhou [Australie] ; Si-Ping Sun [Australie] ; John A. Denman [Australie] ; Thomas R. Gengenbach [Australie] ; Nicolas Barraud [Australie] ; Scott A. Rice [Australie] ; Jian Li [Australie] ; Mingshi Yang [Danemark] ; Hak-Kim Chan [Australie]

Source :

The AAPS journal [ 1550-7416 ] ; 2016.

RBID : pubmed:26603890

Descripteurs français

KwdFr :
- Administration par inhalation, Antibactériens (), Antibactériens (administration et posologie), Aérosols, Colistine (), Colistine (administration et posologie), Infections de l'appareil respiratoire (traitement médicamenteux), Inhalateurs à poudre sèche (), Propriétés de surface (), Pseudomonas aeruginosa (), Pseudomonas aeruginosa (physiologie), Rifampicine (), Rifampicine (administration et posologie), Solubilité, Taille de particule, Tests de sensibilité microbienne ().
MESH :
- administration et posologie : Antibactériens, Colistine, Rifampicine.
- physiologie : Pseudomonas aeruginosa.
- traitement médicamenteux : Infections de l'appareil respiratoire.
- Administration par inhalation, Antibactériens, Aérosols, Colistine, Inhalateurs à poudre sèche, Propriétés de surface, Pseudomonas aeruginosa, Rifampicine, Solubilité, Taille de particule, Tests de sensibilité microbienne.

English descriptors

KwdEn :
- Administration, Inhalation, Aerosols, Anti-Bacterial Agents (administration & dosage), Anti-Bacterial Agents (chemistry), Colistin (administration & dosage), Colistin (chemistry), Dry Powder Inhalers (methods), Microbial Sensitivity Tests (methods), Particle Size, Pseudomonas aeruginosa (drug effects), Pseudomonas aeruginosa (physiology), Respiratory Tract Infections (drug therapy), Rifampin (administration & dosage), Rifampin (chemistry), Solubility, Surface Properties (drug effects).
MESH :
- chemical , administration & dosage : Anti-Bacterial Agents, Colistin, Rifampin.
- chemical , chemistry : Anti-Bacterial Agents, Colistin, Rifampin.
- chemical : Aerosols.
- drug effects : Pseudomonas aeruginosa, Surface Properties.
- drug therapy : Respiratory Tract Infections.
- methods : Dry Powder Inhalers, Microbial Sensitivity Tests.
- physiology : Pseudomonas aeruginosa.
- Administration, Inhalation, Particle Size, Solubility.

Abstract

Colistin is often the only effective antibiotic against the respiratory infections caused by multidrug-resistant Gram-negative bacteria. However, colistin-resistant multidrug-resistant isolates have been increasingly reported and combination therapy is preferred to combat resistance. In this study, five combination formulations containing colistin (COL) and rifampicin (RIF) were prepared by spray drying. The lowest minimum inhibitory concentration (MIC) value against Pseudomonas aeruginosa PAO1 was measured for the formulation of COL/RIF = 4:1 with relatively high emitted doses (over 80%) and satisfactory fine particle fractions (over 60%). Data from X-ray photoelectron spectroscopy (XPS) and nano-time-of-flight secondary ion mass spectrometry (ToF-SIMS) showed the surfaces of particles were mainly covered by rifampicin even for the formulation with a mass ratio of COL/RIF = 4:1. Because colistin is hygroscopic and rifampicin is hydrophobic, moisture absorption of combination formulations was significantly lower than the pure colistin formulation in the dynamic vapour sorption results. To investigate the dissolution characteristics, four dissolution test methods (diffusion Franz cell, modified Franz cell, flow-through and beaker methods) were employed and compared. The modified Franz cell method was selected to test the dissolution behaviour of aerosolised powder formulations to eliminate the effect of membrane on dissolution. The results showed that surface enrichment of hydrophobic rifampicin neither affected aerosolisation nor retarded dissolution rate of colistin in the combination formulations. For the first time, advanced surface characterisation techniques of XPS and ToF-SIMS have shown their capability to understand the effect of surface composition on the aerosolisation and dissolution of combination powders.

DOI: 10.1208/s12248-015-9848-z
PubMed: 26603890

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002210

Links to Exploration step

pubmed:26603890

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effects of Surface Composition on the Aerosolisation and Dissolution of Inhaled Antibiotic Combination Powders Consisting of Colistin and Rifampicin.</title>
<author><name sortKey="Wang, Wenbo" sort="Wang, Wenbo" uniqKey="Wang W" first="Wenbo" last="Wang">Wenbo Wang</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacy, University of Copenhagen, Universitetsparken 2, 2100, Copenhagen, Denmark.</nlm:affiliation>
<country xml:lang="fr">Danemark</country>
<wicri:regionArea>Department of Pharmacy, University of Copenhagen, Universitetsparken 2, 2100, Copenhagen</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Zhou, Qi Tony" sort="Zhou, Qi Tony" uniqKey="Zhou Q" first="Qi Tony" last="Zhou">Qi Tony Zhou</name>
<affiliation wicri:level="1"><nlm:affiliation>Advanced Drug Delivery Group, Faculty of Pharmacy, The University of Sydney, Sydney, NSW, 2006, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Advanced Drug Delivery Group, Faculty of Pharmacy, The University of Sydney, Sydney, NSW, 2006</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Sun, Si Ping" sort="Sun, Si Ping" uniqKey="Sun S" first="Si-Ping" last="Sun">Si-Ping Sun</name>
<affiliation wicri:level="1"><nlm:affiliation>Advanced Drug Delivery Group, Faculty of Pharmacy, The University of Sydney, Sydney, NSW, 2006, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Advanced Drug Delivery Group, Faculty of Pharmacy, The University of Sydney, Sydney, NSW, 2006</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Denman, John A" sort="Denman, John A" uniqKey="Denman J" first="John A" last="Denman">John A. Denman</name>
<affiliation wicri:level="1"><nlm:affiliation>Ian Wark Research Institute, University of South Australia, Mawson Lakes, South Australia, 5095, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Ian Wark Research Institute, University of South Australia, Mawson Lakes, South Australia, 5095</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Gengenbach, Thomas R" sort="Gengenbach, Thomas R" uniqKey="Gengenbach T" first="Thomas R" last="Gengenbach">Thomas R. Gengenbach</name>
<affiliation wicri:level="1"><nlm:affiliation>CSIRO Manufacturing, Bayview Avenue, Clayton, Victoria, 3168, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>CSIRO Manufacturing, Bayview Avenue, Clayton, Victoria, 3168</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Barraud, Nicolas" sort="Barraud, Nicolas" uniqKey="Barraud N" first="Nicolas" last="Barraud">Nicolas Barraud</name>
<affiliation wicri:level="1"><nlm:affiliation>Centre for Marine Bio-Innovation and School of Biotechnology and Biomolecular Sciences, The University of New South Wales, Sydney, NSW, 2052, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Centre for Marine Bio-Innovation and School of Biotechnology and Biomolecular Sciences, The University of New South Wales, Sydney, NSW, 2052</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Rice, Scott A" sort="Rice, Scott A" uniqKey="Rice S" first="Scott A" last="Rice">Scott A. Rice</name>
<affiliation wicri:level="1"><nlm:affiliation>Centre for Marine Bio-Innovation and School of Biotechnology and Biomolecular Sciences, The University of New South Wales, Sydney, NSW, 2052, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Centre for Marine Bio-Innovation and School of Biotechnology and Biomolecular Sciences, The University of New South Wales, Sydney, NSW, 2052</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Li, Jian" sort="Li, Jian" uniqKey="Li J" first="Jian" last="Li">Jian Li</name>
<affiliation wicri:level="1"><nlm:affiliation>Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Yang, Mingshi" sort="Yang, Mingshi" uniqKey="Yang M" first="Mingshi" last="Yang">Mingshi Yang</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacy, University of Copenhagen, Universitetsparken 2, 2100, Copenhagen, Denmark. my@farma.ku.dk.</nlm:affiliation>
<country xml:lang="fr">Danemark</country>
<wicri:regionArea>Department of Pharmacy, University of Copenhagen, Universitetsparken 2, 2100, Copenhagen</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Chan, Hak Kim" sort="Chan, Hak Kim" uniqKey="Chan H" first="Hak-Kim" last="Chan">Hak-Kim Chan</name>
<affiliation wicri:level="1"><nlm:affiliation>Advanced Drug Delivery Group, Faculty of Pharmacy, The University of Sydney, Sydney, NSW, 2006, Australia. kim.chan@sydney.edu.au.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Advanced Drug Delivery Group, Faculty of Pharmacy, The University of Sydney, Sydney, NSW, 2006</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2016">2016</date>
<idno type="RBID">pubmed:26603890</idno>
<idno type="pmid">26603890</idno>
<idno type="doi">10.1208/s12248-015-9848-z</idno>
<idno type="wicri:Area/PubMed/Corpus">002210</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002210</idno>
<idno type="wicri:Area/PubMed/Curation">002184</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002184</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Effects of Surface Composition on the Aerosolisation and Dissolution of Inhaled Antibiotic Combination Powders Consisting of Colistin and Rifampicin.</title>
<author><name sortKey="Wang, Wenbo" sort="Wang, Wenbo" uniqKey="Wang W" first="Wenbo" last="Wang">Wenbo Wang</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacy, University of Copenhagen, Universitetsparken 2, 2100, Copenhagen, Denmark.</nlm:affiliation>
<country xml:lang="fr">Danemark</country>
<wicri:regionArea>Department of Pharmacy, University of Copenhagen, Universitetsparken 2, 2100, Copenhagen</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Zhou, Qi Tony" sort="Zhou, Qi Tony" uniqKey="Zhou Q" first="Qi Tony" last="Zhou">Qi Tony Zhou</name>
<affiliation wicri:level="1"><nlm:affiliation>Advanced Drug Delivery Group, Faculty of Pharmacy, The University of Sydney, Sydney, NSW, 2006, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Advanced Drug Delivery Group, Faculty of Pharmacy, The University of Sydney, Sydney, NSW, 2006</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Sun, Si Ping" sort="Sun, Si Ping" uniqKey="Sun S" first="Si-Ping" last="Sun">Si-Ping Sun</name>
<affiliation wicri:level="1"><nlm:affiliation>Advanced Drug Delivery Group, Faculty of Pharmacy, The University of Sydney, Sydney, NSW, 2006, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Advanced Drug Delivery Group, Faculty of Pharmacy, The University of Sydney, Sydney, NSW, 2006</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Denman, John A" sort="Denman, John A" uniqKey="Denman J" first="John A" last="Denman">John A. Denman</name>
<affiliation wicri:level="1"><nlm:affiliation>Ian Wark Research Institute, University of South Australia, Mawson Lakes, South Australia, 5095, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Ian Wark Research Institute, University of South Australia, Mawson Lakes, South Australia, 5095</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Gengenbach, Thomas R" sort="Gengenbach, Thomas R" uniqKey="Gengenbach T" first="Thomas R" last="Gengenbach">Thomas R. Gengenbach</name>
<affiliation wicri:level="1"><nlm:affiliation>CSIRO Manufacturing, Bayview Avenue, Clayton, Victoria, 3168, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>CSIRO Manufacturing, Bayview Avenue, Clayton, Victoria, 3168</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Barraud, Nicolas" sort="Barraud, Nicolas" uniqKey="Barraud N" first="Nicolas" last="Barraud">Nicolas Barraud</name>
<affiliation wicri:level="1"><nlm:affiliation>Centre for Marine Bio-Innovation and School of Biotechnology and Biomolecular Sciences, The University of New South Wales, Sydney, NSW, 2052, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Centre for Marine Bio-Innovation and School of Biotechnology and Biomolecular Sciences, The University of New South Wales, Sydney, NSW, 2052</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Rice, Scott A" sort="Rice, Scott A" uniqKey="Rice S" first="Scott A" last="Rice">Scott A. Rice</name>
<affiliation wicri:level="1"><nlm:affiliation>Centre for Marine Bio-Innovation and School of Biotechnology and Biomolecular Sciences, The University of New South Wales, Sydney, NSW, 2052, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Centre for Marine Bio-Innovation and School of Biotechnology and Biomolecular Sciences, The University of New South Wales, Sydney, NSW, 2052</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Li, Jian" sort="Li, Jian" uniqKey="Li J" first="Jian" last="Li">Jian Li</name>
<affiliation wicri:level="1"><nlm:affiliation>Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Yang, Mingshi" sort="Yang, Mingshi" uniqKey="Yang M" first="Mingshi" last="Yang">Mingshi Yang</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacy, University of Copenhagen, Universitetsparken 2, 2100, Copenhagen, Denmark. my@farma.ku.dk.</nlm:affiliation>
<country xml:lang="fr">Danemark</country>
<wicri:regionArea>Department of Pharmacy, University of Copenhagen, Universitetsparken 2, 2100, Copenhagen</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Chan, Hak Kim" sort="Chan, Hak Kim" uniqKey="Chan H" first="Hak-Kim" last="Chan">Hak-Kim Chan</name>
<affiliation wicri:level="1"><nlm:affiliation>Advanced Drug Delivery Group, Faculty of Pharmacy, The University of Sydney, Sydney, NSW, 2006, Australia. kim.chan@sydney.edu.au.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Advanced Drug Delivery Group, Faculty of Pharmacy, The University of Sydney, Sydney, NSW, 2006</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series><title level="j">The AAPS journal</title>
<idno type="eISSN">1550-7416</idno>
<imprint><date when="2016" type="published">2016</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Inhalation</term>
<term>Aerosols</term>
<term>Anti-Bacterial Agents (administration & dosage)</term>
<term>Anti-Bacterial Agents (chemistry)</term>
<term>Colistin (administration & dosage)</term>
<term>Colistin (chemistry)</term>
<term>Dry Powder Inhalers (methods)</term>
<term>Microbial Sensitivity Tests (methods)</term>
<term>Particle Size</term>
<term>Pseudomonas aeruginosa (drug effects)</term>
<term>Pseudomonas aeruginosa (physiology)</term>
<term>Respiratory Tract Infections (drug therapy)</term>
<term>Rifampin (administration & dosage)</term>
<term>Rifampin (chemistry)</term>
<term>Solubility</term>
<term>Surface Properties (drug effects)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Administration par inhalation</term>
<term>Antibactériens ()</term>
<term>Antibactériens (administration et posologie)</term>
<term>Aérosols</term>
<term>Colistine ()</term>
<term>Colistine (administration et posologie)</term>
<term>Infections de l'appareil respiratoire (traitement médicamenteux)</term>
<term>Inhalateurs à poudre sèche ()</term>
<term>Propriétés de surface ()</term>
<term>Pseudomonas aeruginosa ()</term>
<term>Pseudomonas aeruginosa (physiologie)</term>
<term>Rifampicine ()</term>
<term>Rifampicine (administration et posologie)</term>
<term>Solubilité</term>
<term>Taille de particule</term>
<term>Tests de sensibilité microbienne ()</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Anti-Bacterial Agents</term>
<term>Colistin</term>
<term>Rifampin</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Anti-Bacterial Agents</term>
<term>Colistin</term>
<term>Rifampin</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en"><term>Aerosols</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Antibactériens</term>
<term>Colistine</term>
<term>Rifampicine</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Pseudomonas aeruginosa</term>
<term>Surface Properties</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Respiratory Tract Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Dry Powder Inhalers</term>
<term>Microbial Sensitivity Tests</term>
</keywords>
<keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Pseudomonas aeruginosa</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Pseudomonas aeruginosa</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections de l'appareil respiratoire</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Administration, Inhalation</term>
<term>Particle Size</term>
<term>Solubility</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Administration par inhalation</term>
<term>Antibactériens</term>
<term>Aérosols</term>
<term>Colistine</term>
<term>Inhalateurs à poudre sèche</term>
<term>Propriétés de surface</term>
<term>Pseudomonas aeruginosa</term>
<term>Rifampicine</term>
<term>Solubilité</term>
<term>Taille de particule</term>
<term>Tests de sensibilité microbienne</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Colistin is often the only effective antibiotic against the respiratory infections caused by multidrug-resistant Gram-negative bacteria. However, colistin-resistant multidrug-resistant isolates have been increasingly reported and combination therapy is preferred to combat resistance. In this study, five combination formulations containing colistin (COL) and rifampicin (RIF) were prepared by spray drying. The lowest minimum inhibitory concentration (MIC) value against Pseudomonas aeruginosa PAO1 was measured for the formulation of COL/RIF = 4:1 with relatively high emitted doses (over 80%) and satisfactory fine particle fractions (over 60%). Data from X-ray photoelectron spectroscopy (XPS) and nano-time-of-flight secondary ion mass spectrometry (ToF-SIMS) showed the surfaces of particles were mainly covered by rifampicin even for the formulation with a mass ratio of COL/RIF = 4:1. Because colistin is hygroscopic and rifampicin is hydrophobic, moisture absorption of combination formulations was significantly lower than the pure colistin formulation in the dynamic vapour sorption results. To investigate the dissolution characteristics, four dissolution test methods (diffusion Franz cell, modified Franz cell, flow-through and beaker methods) were employed and compared. The modified Franz cell method was selected to test the dissolution behaviour of aerosolised powder formulations to eliminate the effect of membrane on dissolution. The results showed that surface enrichment of hydrophobic rifampicin neither affected aerosolisation nor retarded dissolution rate of colistin in the combination formulations. For the first time, advanced surface characterisation techniques of XPS and ToF-SIMS have shown their capability to understand the effect of surface composition on the aerosolisation and dissolution of combination powders.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26603890</PMID>
<DateCreated><Year>2016</Year>
<Month>03</Month>
<Day>05</Day>
</DateCreated>
<DateCompleted><Year>2016</Year>
<Month>12</Month>
<Day>13</Day>
</DateCompleted>
<DateRevised><Year>2017</Year>
<Month>02</Month>
<Day>20</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1550-7416</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>18</Volume>
<Issue>2</Issue>
<PubDate><Year>2016</Year>
<Month>Mar</Month>
</PubDate>
</JournalIssue>
<Title>The AAPS journal</Title>
<ISOAbbreviation>AAPS J</ISOAbbreviation>
</Journal>
<ArticleTitle>Effects of Surface Composition on the Aerosolisation and Dissolution of Inhaled Antibiotic Combination Powders Consisting of Colistin and Rifampicin.</ArticleTitle>
<Pagination><MedlinePgn>372-84</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1208/s12248-015-9848-z</ELocationID>
<Abstract><AbstractText>Colistin is often the only effective antibiotic against the respiratory infections caused by multidrug-resistant Gram-negative bacteria. However, colistin-resistant multidrug-resistant isolates have been increasingly reported and combination therapy is preferred to combat resistance. In this study, five combination formulations containing colistin (COL) and rifampicin (RIF) were prepared by spray drying. The lowest minimum inhibitory concentration (MIC) value against Pseudomonas aeruginosa PAO1 was measured for the formulation of COL/RIF = 4:1 with relatively high emitted doses (over 80%) and satisfactory fine particle fractions (over 60%). Data from X-ray photoelectron spectroscopy (XPS) and nano-time-of-flight secondary ion mass spectrometry (ToF-SIMS) showed the surfaces of particles were mainly covered by rifampicin even for the formulation with a mass ratio of COL/RIF = 4:1. Because colistin is hygroscopic and rifampicin is hydrophobic, moisture absorption of combination formulations was significantly lower than the pure colistin formulation in the dynamic vapour sorption results. To investigate the dissolution characteristics, four dissolution test methods (diffusion Franz cell, modified Franz cell, flow-through and beaker methods) were employed and compared. The modified Franz cell method was selected to test the dissolution behaviour of aerosolised powder formulations to eliminate the effect of membrane on dissolution. The results showed that surface enrichment of hydrophobic rifampicin neither affected aerosolisation nor retarded dissolution rate of colistin in the combination formulations. For the first time, advanced surface characterisation techniques of XPS and ToF-SIMS have shown their capability to understand the effect of surface composition on the aerosolisation and dissolution of combination powders.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName>
<ForeName>Wenbo</ForeName>
<Initials>W</Initials>
<AffiliationInfo><Affiliation>Department of Pharmacy, University of Copenhagen, Universitetsparken 2, 2100, Copenhagen, Denmark.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Zhou</LastName>
<ForeName>Qi Tony</ForeName>
<Initials>QT</Initials>
<AffiliationInfo><Affiliation>Advanced Drug Delivery Group, Faculty of Pharmacy, The University of Sydney, Sydney, NSW, 2006, Australia.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Department of Industrial and Physical Pharmacy, College of Pharmacy, Purdue University, West Lafayette, Indiana, 47907-2091, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Sun</LastName>
<ForeName>Si-Ping</ForeName>
<Initials>SP</Initials>
<AffiliationInfo><Affiliation>Advanced Drug Delivery Group, Faculty of Pharmacy, The University of Sydney, Sydney, NSW, 2006, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Denman</LastName>
<ForeName>John A</ForeName>
<Initials>JA</Initials>
<AffiliationInfo><Affiliation>Ian Wark Research Institute, University of South Australia, Mawson Lakes, South Australia, 5095, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Gengenbach</LastName>
<ForeName>Thomas R</ForeName>
<Initials>TR</Initials>
<AffiliationInfo><Affiliation>CSIRO Manufacturing, Bayview Avenue, Clayton, Victoria, 3168, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Barraud</LastName>
<ForeName>Nicolas</ForeName>
<Initials>N</Initials>
<AffiliationInfo><Affiliation>Centre for Marine Bio-Innovation and School of Biotechnology and Biomolecular Sciences, The University of New South Wales, Sydney, NSW, 2052, Australia.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Department of Microbiology, Genetics of Biofilms Unit, Institut Pasteur, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Rice</LastName>
<ForeName>Scott A</ForeName>
<Initials>SA</Initials>
<AffiliationInfo><Affiliation>Centre for Marine Bio-Innovation and School of Biotechnology and Biomolecular Sciences, The University of New South Wales, Sydney, NSW, 2052, Australia.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Singapore Centre for Environmental Life Sciences Engineering, and the School of Biological Sciences, Nanyang Technological University, Singapore, Singapore.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Li</LastName>
<ForeName>Jian</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Yang</LastName>
<ForeName>Mingshi</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Department of Pharmacy, University of Copenhagen, Universitetsparken 2, 2100, Copenhagen, Denmark. my@farma.ku.dk.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Chan</LastName>
<ForeName>Hak-Kim</ForeName>
<Initials>HK</Initials>
<AffiliationInfo><Affiliation>Advanced Drug Delivery Group, Faculty of Pharmacy, The University of Sydney, Sydney, NSW, 2006, Australia. kim.chan@sydney.edu.au.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>R01 AI098771</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R01 AI111965</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R01 A1098771</GrantID>
<Agency>PHS HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2015</Year>
<Month>11</Month>
<Day>24</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>AAPS J</MedlineTA>
<NlmUniqueID>101223209</NlmUniqueID>
<ISSNLinking>1550-7416</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000336">Aerosols</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>VJT6J7R4TR</RegistryNumber>
<NameOfSubstance UI="D012293">Rifampin</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>Z67X93HJG1</RegistryNumber>
<NameOfSubstance UI="D003091">Colistin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Pharm Res. 2000 Aug;17(8):955-61</RefSource>
<PMID Version="1">11028941</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Respir Med. 2008 Apr;102(4):593-604</RefSource>
<PMID Version="1">18083019</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Drug Dev Ind Pharm. 2001 Nov;27(10):1017-30</RefSource>
<PMID Version="1">11794804</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Int J Pharm. 2003 Apr 14;255(1-2):175-87</RefSource>
<PMID Version="1">12672613</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Pharm Pharmacol. 1981 May;33(5):269-73</RefSource>
<PMID Version="1">6116772</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Appl Physiol (1985). 1986 Feb;60(2):532-8</RefSource>
<PMID Version="1">3512509</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Allergy Asthma Immunol. 2004 Nov;93(5):439-46</RefSource>
<PMID Version="1">15562882</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Int J Antimicrob Agents. 2005 Jan;25(1):11-25</RefSource>
<PMID Version="1">15620821</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Pharm Res. 2005 Jun;22(6):923-32</RefSource>
<PMID Version="1">15948036</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet Infect Dis. 2006 Sep;6(9):589-601</RefSource>
<PMID Version="1">16931410</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Pharm Res. 2007 Feb;24(2):203-27</RefSource>
<PMID Version="1">17191094</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Crit Rev Ther Drug Carrier Syst. 2007;24(4):307-60</RefSource>
<PMID Version="1">18197788</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Pharm Res. 2008 Jul;25(7):1696-701</RefSource>
<PMID Version="1">18320295</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Pharm Sci. 2008 Aug;97(8):3356-66</RefSource>
<PMID Version="1">17990305</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Int J Antimicrob Agents. 2008 Sep;32(3):281-4</RefSource>
<PMID Version="1">18650070</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Eur J Pharm Biopharm. 2008 Sep;70(1):145-52</RefSource>
<PMID Version="1">18534832</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Pharm Sci. 2009 Apr;98(4):1463-75</RefSource>
<PMID Version="1">18752304</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Eur J Pharm Sci. 2010 Aug 11;40(5):412-21</RefSource>
<PMID Version="1">20433919</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Pharm Res. 2011 Apr;28(4):788-96</RefSource>
<PMID Version="1">21136142</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Pharm Sci. 2011 Aug;100(8):3421-30</RefSource>
<PMID Version="1">21455980</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Antimicrob Agents Chemother. 2011 Jul;55(7):3284-94</RefSource>
<PMID Version="1">21555763</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Int J Pharm. 2011 Dec 15;421(2):220-9</RefSource>
<PMID Version="1">21963471</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Pharm Res. 2012 Aug;29(8):2157-66</RefSource>
<PMID Version="1">22528980</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>AAPS PharmSciTech. 2012 Sep;13(3):978-89</RefSource>
<PMID Version="1">22798037</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Cyst Fibros. 2012 Dec;11(6):461-79</RefSource>
<PMID Version="1">23137712</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Pharm Res. 2013 Apr;30(4):1065-76</RefSource>
<PMID Version="1">23263784</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Int J Pharm. 2013 Apr 15;447(1-2):251-80</RefSource>
<PMID Version="1">23499756</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Pharm Sci. 2013 Oct;102(10):3736-47</RefSource>
<PMID Version="1">23904207</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2013;8(12):e84220</RefSource>
<PMID Version="1">24349568</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>AAPS J. 2014 Jan;16(1):37-47</RefSource>
<PMID Version="1">24129586</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Antimicrob Agents Chemother. 2014 May;58(5):2570-9</RefSource>
<PMID Version="1">24550334</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Eur J Pharm Biopharm. 2013 Feb;83(2):285-92</RefSource>
<PMID Version="1">22982733</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Eur J Pharm Biopharm. 2013 Feb;83(2):275-84</RefSource>
<PMID Version="1">23010564</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Eur J Pharm Biopharm. 2013 Feb;83(2):234-43</RefSource>
<PMID Version="1">23183447</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Adv Drug Deliv Rev. 2014 Aug;75:3-17</RefSource>
<PMID Version="1">24732364</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Adv Drug Deliv Rev. 2015 May;85:65-82</RefSource>
<PMID Version="1">25446140</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Adv Drug Deliv Rev. 2015 May;85:83-99</RefSource>
<PMID Version="1">25451137</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mol Pharm. 2015 Aug 3;12(8):2594-603</RefSource>
<PMID Version="1">25423590</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Adv Drug Deliv Rev. 2001 May 16;48(1):91-114</RefSource>
<PMID Version="1">11325478</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000280" MajorTopicYN="N">Administration, Inhalation</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000336" MajorTopicYN="N">Aerosols</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003091" MajorTopicYN="N">Colistin</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058995" MajorTopicYN="Y">Dry Powder Inhalers</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008826" MajorTopicYN="N">Microbial Sensitivity Tests</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010316" MajorTopicYN="N">Particle Size</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011550" MajorTopicYN="N">Pseudomonas aeruginosa</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012141" MajorTopicYN="N">Respiratory Tract Infections</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012293" MajorTopicYN="N">Rifampin</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012995" MajorTopicYN="N">Solubility</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013499" MajorTopicYN="N">Surface Properties</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4779103 [Available on 11/24/16]</OtherID>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">colistin</Keyword>
<Keyword MajorTopicYN="N">combination antibiotics</Keyword>
<Keyword MajorTopicYN="N">dry powder inhaler</Keyword>
<Keyword MajorTopicYN="N">respiratory infection</Keyword>
<Keyword MajorTopicYN="N">rifampicin</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year>
<Month>08</Month>
<Day>07</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2015</Year>
<Month>11</Month>
<Day>15</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2015</Year>
<Month>11</Month>
<Day>26</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2015</Year>
<Month>11</Month>
<Day>26</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2016</Year>
<Month>12</Month>
<Day>15</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">26603890</ArticleId>
<ArticleId IdType="doi">10.1208/s12248-015-9848-z</ArticleId>
<ArticleId IdType="pii">10.1208/s12248-015-9848-z</ArticleId>
<ArticleId IdType="pmc">PMC4779103</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002184 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 002184 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PubMed
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:26603890
   |texte=   Effects of Surface Composition on the Aerosolisation and Dissolution of Inhaled Antibiotic Combination Powders Consisting of Colistin and Rifampicin.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i   -Sk "pubmed:26603890" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a AustralieFrV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Effects of Surface Composition on the Aerosolisation and Dissolution of Inhaled Antibiotic Combination Powders Consisting of Colistin and Rifampicin.

Effects of Surface Composition on the Aerosolisation and Dissolution of Inhaled Antibiotic Combination Powders Consisting of Colistin and Rifampicin.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki